This study is comparing two cancer treatments for adults with a type of lung cancer called metastatic non-small cell lung cancer (NSCLC). "Metastatic" means the cancer has spread to other parts of the body. Researchers want to see if combining two drugs, pembrolizumab and sacituzumab govitecan, works better than using pembrolizumab alone. Pembrolizumab helps the immune system fight cancer by targeting a protein called programmed cell death ligand 1 (PD-L1), which helps cancer cells hide from the immune system. Patients must have a PD-L1 tumor proportion score (TPS) of 50% or more to join the study.

• The study tests pembrolizumab alone or with sacituzumab govitecan.
• Participants need to have certain types of lung cancer and a PD-L1 TPS ≥50%.
• Exclusions include other cancers, prior treatments, or certain health conditions.

People should consider their health history and talk to their doctor to see if they qualify and if the study is a good fit for them. The study's goal is to improve survival and manage cancer growth. Participants should understand the potential risks and benefits before enrolling.